| Dr Tae Rho, MD | |
|
1301 Punchbowl St, Honolulu, HI 96813-2402 | |
| (808) 521-9551 | |
| (808) 536-3008 |
| Full Name | Dr Tae Rho |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 40 Years |
| Location | 1301 Punchbowl St, Honolulu, Hawaii |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164402434 | NPI | - | NPPES |
| 251283 | Medicaid | HI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085N0700X | Radiology - Neuroradiology | 10786 (Hawaii) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Queens Medical Center | Honolulu, HI | Hospital |
| North Hawaii Community Hospital | Kamuela, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Queen's North Hawaii Community Hospital | 0143116293 | 58 |
| Queens University Medical Group | 2466831557 | 543 |
News Archive
Today's headlines include stories about how Medicare might fit into the next round of budget talks.
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy.
Trauma is a leading cause of disability in the world, resulting in more disability-adjusted life years than any other disease. While in-hospital, trauma-related mortality has decreased to just 4 percent in the U.S., little is known about what happens to the 96 percent of patients who survive their trauma injuries but may suffer debilitating long-term effects.
A new preprint recently released on the bioRxiv* server describes the immunogenicity and protective potential of a novel adenovirus SARS-CoV-2 vaccine candidate against a form of the virus adapted to cause severe disease in mice. The findings show that this provides a useful mouse model for the study of new vaccines, in addition to demonstrating the protective efficacy of the current rhesus adenovirus vaccine candidate RhAd52.
› Verified 8 days ago
| Entity Name | Queen's North Hawaii Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528049814 PECOS PAC ID: 0143116293 Enrollment ID: O20040225000562 |
News Archive
Today's headlines include stories about how Medicare might fit into the next round of budget talks.
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy.
Trauma is a leading cause of disability in the world, resulting in more disability-adjusted life years than any other disease. While in-hospital, trauma-related mortality has decreased to just 4 percent in the U.S., little is known about what happens to the 96 percent of patients who survive their trauma injuries but may suffer debilitating long-term effects.
A new preprint recently released on the bioRxiv* server describes the immunogenicity and protective potential of a novel adenovirus SARS-CoV-2 vaccine candidate against a form of the virus adapted to cause severe disease in mice. The findings show that this provides a useful mouse model for the study of new vaccines, in addition to demonstrating the protective efficacy of the current rhesus adenovirus vaccine candidate RhAd52.
› Verified 8 days ago
| Entity Name | Radiology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205885134 PECOS PAC ID: 5395634364 Enrollment ID: O20040315001300 |
News Archive
Today's headlines include stories about how Medicare might fit into the next round of budget talks.
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy.
Trauma is a leading cause of disability in the world, resulting in more disability-adjusted life years than any other disease. While in-hospital, trauma-related mortality has decreased to just 4 percent in the U.S., little is known about what happens to the 96 percent of patients who survive their trauma injuries but may suffer debilitating long-term effects.
A new preprint recently released on the bioRxiv* server describes the immunogenicity and protective potential of a novel adenovirus SARS-CoV-2 vaccine candidate against a form of the virus adapted to cause severe disease in mice. The findings show that this provides a useful mouse model for the study of new vaccines, in addition to demonstrating the protective efficacy of the current rhesus adenovirus vaccine candidate RhAd52.
› Verified 8 days ago
| Entity Name | Queens University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891441382 PECOS PAC ID: 2466831557 Enrollment ID: O20220621000534 |
News Archive
Today's headlines include stories about how Medicare might fit into the next round of budget talks.
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy.
Trauma is a leading cause of disability in the world, resulting in more disability-adjusted life years than any other disease. While in-hospital, trauma-related mortality has decreased to just 4 percent in the U.S., little is known about what happens to the 96 percent of patients who survive their trauma injuries but may suffer debilitating long-term effects.
A new preprint recently released on the bioRxiv* server describes the immunogenicity and protective potential of a novel adenovirus SARS-CoV-2 vaccine candidate against a form of the virus adapted to cause severe disease in mice. The findings show that this provides a useful mouse model for the study of new vaccines, in addition to demonstrating the protective efficacy of the current rhesus adenovirus vaccine candidate RhAd52.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tae Rho, MD 500 Ala Moana Blvd, Tower 4, Suite 510, Honolulu, HI 96813-4920 Ph: (808) 521-9551 | Dr Tae Rho, MD 1301 Punchbowl St, Honolulu, HI 96813-2402 Ph: (808) 521-9551 |
News Archive
Today's headlines include stories about how Medicare might fit into the next round of budget talks.
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy.
Trauma is a leading cause of disability in the world, resulting in more disability-adjusted life years than any other disease. While in-hospital, trauma-related mortality has decreased to just 4 percent in the U.S., little is known about what happens to the 96 percent of patients who survive their trauma injuries but may suffer debilitating long-term effects.
A new preprint recently released on the bioRxiv* server describes the immunogenicity and protective potential of a novel adenovirus SARS-CoV-2 vaccine candidate against a form of the virus adapted to cause severe disease in mice. The findings show that this provides a useful mouse model for the study of new vaccines, in addition to demonstrating the protective efficacy of the current rhesus adenovirus vaccine candidate RhAd52.
› Verified 8 days ago
Dr. Samuel M. Wu, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3288 Moanalua Rd, Honolulu, HI 96819 Phone: 808-432-0000 | |
Dr. Horia Vulpe, MD, CM Radiology Medicare: Accepting Medicare Assignments Practice Location: 1301 Punchbowl St, Honolulu, HI 96813 Phone: 808-691-8777 Fax: 808-691-8780 | |
Howard K. Arimoto, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 347 N Kuakini St, Honolulu, HI 96817 Phone: 808-522-0190 Fax: 808-523-9068 | |
Dr. Mark T. Kanemori, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1650 Liliha St, Suite 105, Honolulu, HI 96817 Phone: 808-524-3131 Fax: 808-524-3189 | |
Dr. Ferdinand K Hui, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 550 S Beretania St Ste 405, Honolulu, HI 96813 Phone: 808-691-8866 | |
Dr. Jean Paul Colon-pons, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1380 Lusitana St Ste 1007, Honolulu, HI 96813 Phone: 808-748-4488 Fax: 808-748-4799 | |
Kristen T. Nagata, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3288 Moanalua Rd, Honolulu, HI 96819 Phone: 808-432-0000 |